Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study

NCT05873790 · clinicaltrials.gov ↗

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Serplulimab plus chemotherapy

Sponsor

The First Hospital of Jilin University